This acetyl-L-carnitine trial found no preventive benefit at its primary assessment and an unfavorable later neuropathy result. The distinction between visits matters when interpreting the safety signal.
What the original trial measured
Women receiving adjuvant taxane chemotherapy for breast cancer entered a randomized, double-blind placebo comparison. Of 437 registered participants, 27 were ineligible and one withdrew consent for follow-up, leaving 409 evaluable participants. Evaluable does not mean every participant supplied every assessment. Original trial report.
| Assessment | Participants assessed | Adjusted ALC minus placebo difference |
|---|---|---|
| 12 weeks, primary | 372 | -0.91 points; 95% CI -2.21 to 0.39; P=.17 |
| 24 weeks, secondary | 347 | -1.80 points; 95% CI -3.16 to -0.43; P=.01 |
ALC means acetyl-L-carnitine. Lower FACT-NTX scores indicate worse neuropathy symptoms. Full report, Tables 2 and 3.
What the longer follow-up adds
The 2018 publication follows the same SWOG S0715 trial; it is not an independent replication. Its longitudinal analysis favored placebo across the two-year observation period. However, the isolated 104-week between-group comparison was not statistically significant (P=.17). Those statements describe different analyses and can both be true. Long-term report, Methods and Table 2; SWOG publication record.
Our interpretation
A proposed protective mechanism is a reason to test a compound, not a substitute for a favorable clinical result. Calling the primary comparison neutral must not erase a later safety concern. Equally, a secondary finding should retain that label instead of being presented as the trial’s original primary result.
The table also prevents a common denominator mistake: the number entering a study, the number eligible for analysis and the number supplying a particular visit’s outcome are not interchangeable. Missing observations deserve attention even when treatment was randomized.
Longitudinal models and single-visit tests answer different questions. The former considers the pattern across repeated observations; the latter examines one visit. Neither should be selected merely because it produces the preferred headline.
Limits of the evidence
The follow-up relied on reported symptoms rather than nerve-conduction testing, and patients with baseline diabetes were excluded. Follow-up discussion. Our appraisal is therefore specific to the studied setting, not a universal estimate of nerve injury.
Prevention during taxane therapy is a different question from treating established neuropathy from another cause. This page does not establish the effects of another carnitine formulation, other chemotherapy regimens or an individual patient’s treatment plan.
Questions for reading this study
Does a nonsignificant primary result establish safety?
No. Failure to demonstrate a benefit is not a safety certificate; adverse outcomes and the study’s ability to detect them require separate consideration.
Should the two publications be counted as two trials?
No. A later report can add follow-up without adding an independent group of participants.
Is this a supplement protocol?
No. This is an educational research appraisal, not dosing or treatment advice. Discuss supplements during cancer treatment with the treating oncology team.
Source review updated October 1, 2026. This summary is not medical advice.